HAVCR2 and neoplasm: Consistent with a role in the negative regulation of anti-tumour immunity, there is extensive pre-clinical data demonstrating the therapeutic benefit of blocking TIM-3 signalling, mostly in conjunction with PD-1 blockade [242].